Evidence map›Paper›PMID 41423505›Full record

Trial reportBritish journal of cancer2026

High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).

Visalini Nair-Shalliker, David P Smith, Val Gebski, Manish I Patel, Mark Frydenberg, John Yaxley, Robert 'Frank' Gardiner, David Espinoza, Michael G Kimlin, Varinderpal Dhillon and 12 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Visalini Nair-ShallikerThe Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia. visalinin@nswcc.org.au.ORCID http://orcid.org/0000-0001-6277-5125
David P SmithThe Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-1474-3214
Val GebskiNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Manish I PatelSchool of Public Health and Preventive Medicine, Monash University, Clayton, VIC, Australia.
Mark FrydenbergDepartment of Surgery, Monash University, Cabrini Institute, Cabrini Health, Clayton, VIC, Australia.
John YaxleyRoyal Brisbane and Women's Hospital, Herston, QLD, Australia.
Robert 'Frank' GardinerUniversity of Queensland, St Lucia, QLD, Australia.
David EspinozaNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Michael G KimlinBond University, Robina, Queensland, Australia.
Varinderpal DhillonClinical and Health Sciences, University of South Australia, Sydney, SA, Australia.
Wayne LeifertThe Commonwealth Scientific and Industrial Research Organisation (CSIRO), Health & Biosecurity, Human Health Program, Sydney, SA, Australia.
David GillattFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
Henry WooDepartment of Urology, Blacktown Hospital, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-4099-0339
Krishan RasiahRoyal North Shore Hospital, Sydney, NSW, Australia.
Nader AwadUrology Centre Port Macquarie, Sydney, NSW, Australia.
James SymonsSchool of Public Health and Preventive Medicine, Monash University, Clayton, VIC, Australia.
Jadon K WellsChildren's Medical Research Institute, Faculty of Medicine and Health, University of Sydney, Westmead, NSW, Australia.
Hilda A PickettChildren's Medical Research Institute, Faculty of Medicine and Health, University of Sydney, Westmead, NSW, Australia.
Michael FenechClinical and Health Sciences, University of South Australia, Sydney, SA, Australia.
Paul H AndersonClinical and Health Sciences, University of South Australia, Sydney, SA, Australia.
Bruce K ArmstrongSchool of Public Health, The University of Western Australia, Perth, WA, Australia.
Howard GurneyFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ProsD trial aimed to determine if oral vitamin D supplementation could prevent prostate cancer (PC) progression in men on active surveillance (AS).

methodsProsD is a phase-II double-blinded randomized trial of newly diagnosed, low-intermediate risk PC cases, aged between 50 and 80 years and on AS. The intervention was a monthly oral dose of cholecalciferol (50,000IU; Vitamin D) or placebo. Primary and secondary endpoints were active therapy-free (ATFS) and progression-free (PFS) survival, respectively. Blood samples were analysed for vitamin D metabolites and cytokinesis-block micronucleus cytome (CBMN) markers for lymphocytic genome damage.

resultsThere were 123 randomised participants (81 vitamin D and 42 placebo) included in this analysis. Mean (SD) for age was 66.5 (6.6) years and for 25(OH)D levels were 72.0 (19.9) and 66.4 (18.4) nmol/L at baseline (p = 0.1), and 91.9 (19.9) and 60.4 (24.4) nmol/L at 24 months, in the vitamin D and placebo arms respectively. There were no appreciable differences in ATFS (p

conclusionVitamin D supplementation did not prevent PC progression, although reduced prevalence of CBMN markers may indicate a benefit of vitamin D supplementation.

trial registrationAustralia New Zealand Clinical Trials Registry (ACTRN12616001707459).

Indexed as

CholecalciferolDietary SupplementsProstatic NeoplasmsVitamin DAgedAged, 80 and overDisease ProgressionDouble-Blind MethodHumansMaleMiddle AgedCholecalciferolVitamin DCalcidiolCalcitriolCBMNGenome damageProstate cancerSupplementationVitamin D

Identifiers

PMID41423505
PMCPMC12905167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.